Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Editorial introductions

Editorial introductions URRENT PINION Current Opinion in HIV and AIDS was launched in 2006. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The fields of HIV and AIDS are divided into nine sections that are reviewed once a year. Each section is assigned one or two Section Editors, leading authorities in the area, who identify the most important topics at that time. Here we are pleased to introduce the Section Editors for this issue. SECTION EDITORS Group for Treatment and Prevention of HIV in Adults, Adolescents, and Children. Charles W. Flexner Angela Kashuba Charles W. Flexner is Professor of Medicine in the Divisions of Clin- Angela Kashuba, B.Sc.Phm., ical Pharmacology and Infectious Pharm.D., DABCP, FCP, is the Diseases, and Professor of Phar- John A and Margaret P McNeill, macology and Molecular Sciences Sr. Distinguished Professor and at the Johns Hopkins University Dean of the UNC Eshelman School of Medicine. He is also School of Pharmacy. She has been Professor of International Health on faculty at the University of at the Bloomberg School of Public North Carolina at Chapel Hill Health. Dr. Flexner is an expert on since 1997 and served as the Chair the basic and clinical pharmacology of drugs for of the Division of Pharmacother- HIV/AIDS and related infections, including viral apy and Experimental Therapeu- hepatitis and tuberculosis. He has published exten- tics from 2015 to 2019. Dr Kashuba serves as sively on antiviral and antibiotic drug transport and Director of the UNC Center for AIDS Research metabolism, and metabolic drug interactions. His Clinical Pharmacology and Analytical Chemistry current research focuses on the discovery and devel- Core and leads a research laboratory focused on opment of new molecules and formulations for optimizing antiretroviral pharmacology in the long-acting parenteral administration for treatment treatment, prevention, and eradication of HIV and prevention of HIV infection. He directs the infection. Her laboratory has authored over 250 Long Acting/Extended Release Antiretroviral manuscripts and received over $25 million in Research Resource Program (LEAP; www.longacting- research funding. She is the recipient of the 2020 hiv.org), which provides advice and support to an ASCPT Rawls–Palmer Progress in Medicine Award, international audience including the World Health 2017 ACCP (Pharmacology) Honorary Fellowship Organization (WHO) and Unitaid. He is Co-Director Award, and 2017 ACCP (Pharmacy) Therapeutic of the Johns Hopkins University Baltimore-Wash- Frontiers Lecture Award. Dr. Kashuba received her ington-India HIV Clinical Trials Unit (BWI CTU), Bachelor’s in Pharmacy Degree from the University and currently chairs the Antiretroviral Strategies of Toronto and her Doctor of Pharmacy Degree from committee of the AIDS Clinical Trials Group. SUNY Buffalo. She completed a residency at Wom- Dr. Flexner is the Chief Scientific Officer of the en’s College Hospital and a clinical pharmacology Institute for Clinical and Translational Research at research fellowship at the Clinical Pharmacology Johns Hopkins, and is a member of the editorial Research Center at Bassett Healthcare in Coopers- board of 12 scientific journals. He currently serves town, NY. on the WHO Clinical Guidelines Development 1746-630X Copyright  2021 Wolters Kluwer Health, Inc. All rights reserved. www.co-hivandaids.com Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and Aids Wolters Kluwer Health

Editorial introductions

Loading next page...
 
/lp/wolters-kluwer-health/editorial-introductions-ggheov3b8T
Publisher
Wolters Kluwer Health
Copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/coh.0000000000000714
Publisher site
See Article on Publisher Site

Abstract

URRENT PINION Current Opinion in HIV and AIDS was launched in 2006. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The fields of HIV and AIDS are divided into nine sections that are reviewed once a year. Each section is assigned one or two Section Editors, leading authorities in the area, who identify the most important topics at that time. Here we are pleased to introduce the Section Editors for this issue. SECTION EDITORS Group for Treatment and Prevention of HIV in Adults, Adolescents, and Children. Charles W. Flexner Angela Kashuba Charles W. Flexner is Professor of Medicine in the Divisions of Clin- Angela Kashuba, B.Sc.Phm., ical Pharmacology and Infectious Pharm.D., DABCP, FCP, is the Diseases, and Professor of Phar- John A and Margaret P McNeill, macology and Molecular Sciences Sr. Distinguished Professor and at the Johns Hopkins University Dean of the UNC Eshelman School of Medicine. He is also School of Pharmacy. She has been Professor of International Health on faculty at the University of at the Bloomberg School of Public North Carolina at Chapel Hill Health. Dr. Flexner is an expert on since 1997 and served as the Chair the basic and clinical pharmacology of drugs for of the Division of Pharmacother- HIV/AIDS and related infections, including viral apy and Experimental Therapeu- hepatitis and tuberculosis. He has published exten- tics from 2015 to 2019. Dr Kashuba serves as sively on antiviral and antibiotic drug transport and Director of the UNC Center for AIDS Research metabolism, and metabolic drug interactions. His Clinical Pharmacology and Analytical Chemistry current research focuses on the discovery and devel- Core and leads a research laboratory focused on opment of new molecules and formulations for optimizing antiretroviral pharmacology in the long-acting parenteral administration for treatment treatment, prevention, and eradication of HIV and prevention of HIV infection. He directs the infection. Her laboratory has authored over 250 Long Acting/Extended Release Antiretroviral manuscripts and received over $25 million in Research Resource Program (LEAP; www.longacting- research funding. She is the recipient of the 2020 hiv.org), which provides advice and support to an ASCPT Rawls–Palmer Progress in Medicine Award, international audience including the World Health 2017 ACCP (Pharmacology) Honorary Fellowship Organization (WHO) and Unitaid. He is Co-Director Award, and 2017 ACCP (Pharmacy) Therapeutic of the Johns Hopkins University Baltimore-Wash- Frontiers Lecture Award. Dr. Kashuba received her ington-India HIV Clinical Trials Unit (BWI CTU), Bachelor’s in Pharmacy Degree from the University and currently chairs the Antiretroviral Strategies of Toronto and her Doctor of Pharmacy Degree from committee of the AIDS Clinical Trials Group. SUNY Buffalo. She completed a residency at Wom- Dr. Flexner is the Chief Scientific Officer of the en’s College Hospital and a clinical pharmacology Institute for Clinical and Translational Research at research fellowship at the Clinical Pharmacology Johns Hopkins, and is a member of the editorial Research Center at Bassett Healthcare in Coopers- board of 12 scientific journals. He currently serves town, NY. on the WHO Clinical Guidelines Development 1746-630X Copyright  2021 Wolters Kluwer Health, Inc. All rights reserved. www.co-hivandaids.com Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Journal

Current Opinion in HIV and AidsWolters Kluwer Health

Published: Jan 1, 2022

There are no references for this article.